# A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

Study · id `cardio:ct-nct07839936` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07839936](<https://clinicaltrials.gov/study/NCT07839936>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07839936

Browse, organ or system: Heart; Blood vessels; Brain; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Stroke; Diabetes and metabolic disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 175 participants.

## Technical summary

Registry record NCT07839936. Randomized; double masking; primary purpose treatment. Start 2026-09-24 (actual); primary completion 2028-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 175 participants (planned count; ClinicalTrials.gov record NCT07839936, source copy `cardio:ctgov-nct07839936-2026-11-10`, retrieved 2026-11-18)
- Started: 2026-09-24 (actual) (ClinicalTrials.gov record NCT07839936, source copy `cardio:ctgov-nct07839936-2026-11-10`, retrieved 2026-11-18)
- Primary completion: 2028-08 (anticipated) (ClinicalTrials.gov record NCT07839936, source copy `cardio:ctgov-nct07839936-2026-11-10`, retrieved 2026-11-18)
- Completion: 2030-03 (anticipated) (ClinicalTrials.gov record NCT07839936, source copy `cardio:ctgov-nct07839936-2026-11-10`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT07839936, source copy `cardio:ctgov-nct07839936-2026-11-10`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07839936-2026-11-10`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
- Acronym: HEART-3
- Condition: Atherosclerosis
- Condition: Cardiovascular Disease
- Condition: Hypercholesterolemia
- Intervention (Drug): VERVE-102
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 1d2516313a4bbe58e4653997fb12cfafe116c40caa45bea8bccfa67b0fc11994
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
